Medication info
Il Yang Dapagliflozin 10 mg (Dapagliflozin Propanediol Hydrate)

Il Yang Dapagliflozin 10 mg (Dapagliflozin Propanediol Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tablet
Manufacturer / importer
Il Yang Pharmaceutical Co., Ltd.
Appearance
Yellow, biconvex, diamond-shaped film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle, 28 tablets/box [(7 tablets/Alu-Alu)x4]
Approval status
Active

MFDS item code 202200328 · Approved 2022.01.20 · Insurance code 641706130

Summary

Main use
Improves glycemic control in type 2 diabetes and reduces the risk of progression of chronic kidney disease and death
Who takes it
Adults · Children
Adult dose
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this drug is 10 mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received pharmacological treatment for diabetes, the recommended initial dose of this drug when administered in combination with metformin is 5 mg once daily or 10 mg once daily. Chronic kidney disease The recommended dose of this drug is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this drug to improve glycemic control is not recommended. - eGFR less than 25 mL/min/1.73m2: Initiation of treatment with this drug is not recommended in patients with chronic heart failure or chronic kidney disease. - Patients on dialysis: Do not administer this drug. Hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. A starting dose of 5 mg is recommended for patients with severe hepatic impairment. If well tolerated, this dose may be increased to 10mg. Elderly (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This drug may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
Child dose
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. There are no relevant data.

Ingredients

Manufacturer
Il Yang Pharmaceutical Co., Ltd.

Efficacy & effects

Improves glycemic control in type 2 diabetes and reduces the risk of progression of chronic kidney disease and death

  • Type 2 diabetes
  • abnormal blood sugar control
  • chronic kidney disease
  • decreased glomerular filtration rate
  • end-stage kidney disease
  • cardiovascular disease
View approved original text

This medicine helps improve blood sugar control in patients with type 2 diabetes. It is also used in patients with chronic kidney disease to slow the decline in kidney function and reduce the risk of cardiovascular disease and kidney-related mortality. This medicine is administered alongside dietary and exercise therapy, and is effective in patients at risk for cardiovascular issues. Therefore, it is a useful drug for improving both blood sugar control and kidney health.

How to take

Adult dose

Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this drug is 10 mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received pharmacological treatment for diabetes, the recommended initial dose of this drug when administered in combination with metformin is 5 mg once daily or 10 mg once daily. Chronic kidney disease The recommended dose of this drug is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this drug to improve glycemic control is not recommended. - eGFR less than 25 mL/min/1.73m2: Initiation of treatment with this drug is not recommended in patients with chronic heart failure or chronic kidney disease. - Patients on dialysis: Do not administer this drug. Hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. A starting dose of 5 mg is recommended for patients with severe hepatic impairment. If well tolerated, this dose may be increased to 10mg. Elderly (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This drug may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.

Child dose

The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. There are no relevant data.

Precautions

This medicine should not be administered to patients with hypersensitivity to the active ingredient or excipients, patients with type 1 diabetes, patients with diabetic ketoacidosis, patients with genetic issues such as lactose intolerance, and patients undergoing dialysis. It should be administered cautiously to patients with low fluid volume or impaired kidney function, and blood pressure and kidney function must be carefully monitored before and during treatment. This medicine is not recommended for patients with severely impaired kidney function, and especially for patients with low eGFR, consultation with a doctor is required before starting treatment. The most common side effects upon administration include genital infections, which may occur more frequently in women, so immediate treatment is required if any infection symptoms arise. Hypoglycemic symptoms may occur more frequently when this medicine is used in conjunction with insulin or sulfonylureas; therefore, dosage adjustments of these medications may be necessary. Dehydration or decreased fluid volume may occur, so elderly patients or those taking diuretics should be particularly aware of dehydration symptoms. Severe metabolic abnormalities, such as diabetic ketoacidosis, may rarely occur; therefore, immediate consultation with medical staff and testing is required if symptoms such as nausea, vomiting, abdominal pain, or difficulty breathing arise. Major urinary tract infections such as urinary tract infections and pyelonephritis have been reported, so prompt treatment is required if urinary tract infection symptoms are present. This medicine should be used with caution in patients with severely impaired liver function, and women who are pregnant or breastfeeding should avoid its use. Furthermore, this medicine may interact with certain drugs, so it is important to inform healthcare providers if other medications are being taken. There is no specific antidote for overdose, so appropriate treatment must be received based on symptoms, and caution should be taken regarding hypoglycemic risk when driving or operating machinery. Lastly, the safety and efficacy of this medicine has not been established in children, so it should not be used in pediatric patients.

Side effects

Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, decreased fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, low back pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar pruritus, genital pruritus, elevated hematocrit, decreased early treatment renal creatinine clearance, dyslipidemia, elevated serum creatinine at the start of treatment, elevated blood urea, weight loss, urosepsis, pyelonephritis, acute kidney injury, renal dysfunction, rash, angioedema, asthenia, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina pectoris, myocardial infarction, depression, suicide attempt, gastric adenocarcinoma, anaphylaxis, acute pyelonephritis, chest pain, chronic gastritis, diverticulitis, intragastric air retention, frequent bowel movements, gastroenteritis, colorectal polyp, intestinal perforation, epigastric discomfort, functional dyspepsia, erosive gastritis, gum disorders, gum pain, hemorrhoids, hiatal hernia, irritable bowel syndrome, melena, chronic pancreatitis, gastritis, gastrointestinal disorders, abdominal discomfort, abdominal pain, gastroesophageal reflux disease, esophagitis, lower abdominal pain, upper abdominal pain, enteritis, gastric ulcer, urgency, diabetic nephropathy, overactive bladder, microalbuminuria, pressure urinary incontinence, hesitancy, urinary stones, abnormal urine, increased blood lactate, lymphocytopenia, vitamin D deficiency, decreased appetite, hypoglycemia, dysgeusia, drowsiness, tension headache, carpal tunnel syndrome, diabetic neuropathy, unconsciousness, nerve compression, neuralgia, peripheral neuropathy, sleep disorders, syncope, tremor, bronchitis, herpes zoster, sinusitis, tonsillitis, herpes simplex, stye, joint abscess, laryngitis, otitis media, pelvic inflammatory disease, pericoronitis, pneumonia, pulmonary tuberculosis, rhinitis, onychomycosis, herpes simplex, edema, fever, foreign body sensation, facial swelling, facial pain, warmth, influenza-like symptoms, fatigue, chest discomfort, peripheral edema, generalized edema, hunger, vaginal discharge, menstrual irregularities, itching, urticaria, cold sweat, arthralgia, musculoskeletal pain, limb pain, muscular weakness, myalgia, osteoarthritis, ligament sprains, diabetic retinopathy, cough, dyspnea, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyp, tinnitus

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine may be sensitive to air or moisture, so it should be stored in a tightly closed container. It is recommended to maintain a storage temperature between 1 degree and 30 degrees at room temperature. Proper storage can help maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Yellow, biconvex, diamond-shaped film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle, 28 tablets/box [(7 tablets/Alu-Alu)x4]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.